<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64175</article-id><article-id pub-id-type="doi">10.7554/eLife.64175</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-215183"><name><surname>Öztürk</surname><given-names>Bilge E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5117-077X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215182"><name><surname>Johnson</surname><given-names>Molly E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215184"><name><surname>Kleyman</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215185"><name><surname>Turunç</surname><given-names>Serhan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215186"><name><surname>He</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215187"><name><surname>Jabalameli</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215188"><name><surname>Xi</surname><given-names>Zhouhuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114080"><name><surname>Visel</surname><given-names>Meike</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5033-3730</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-114081"><name><surname>Dufour</surname><given-names>Valérie L</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215189"><name><surname>Iwabe</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114082"><name><surname>Pompeo Marinho</surname><given-names>Felipe</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114084"><name><surname>Aguirre</surname><given-names>Gustavo D</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202065"><name><surname>Sahel</surname><given-names>José-Alain</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-34935"><name><surname>Schaffer</surname><given-names>David V</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-90267"><name><surname>Pfenning</surname><given-names>Andreas R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-16007"><name><surname>Flannery</surname><given-names>John G</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0720-8897</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-215190"><name><surname>Beltran</surname><given-names>William A</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-58861"><name><surname>Stauffer</surname><given-names>William R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1031-8824</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" corresp="yes" id="author-238199"><name><surname>Byrne</surname><given-names>Leah C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3229-4993</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-10"/><xref ref-type="other" rid="par-11"/><xref ref-type="fn" rid="conf9"/></contrib><aff id="aff1"><institution content-type="dept">Ophthalmology</institution>, <institution>University of Pittsburgh</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Computational Biology</institution>, <institution>Carnegie Mellon University</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Neurobiology</institution>, <institution>University of Pittsburgh</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Helen Wills Neuroscience Institute</institution>, <institution>University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Division of Experimental Retinal Therapies, Department of Clinical Sciences &amp; Advanced Medicine</institution>, <institution>University of Pennsylvania</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Clinical Sciences &amp; Advanced Medicine</institution>, <institution>University of Pennsylvania</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Chemical Engineering</institution>, <institution>University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution content-type="dept">Department of Molecular and Cell Biology</institution>, <institution>University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><aff id="aff9"><institution>University of Pittsburgh</institution>, <addr-line><named-content content-type="city">Pittsburgh, PA</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-14341"><name><surname>Harvey</surname><given-names>Brandon K</given-names></name><role>Reviewing editor</role><aff><institution>NIDA/NIH</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>lctbyrne@gmail.com</email> (LB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>10</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e64175</elocation-id><history><date date-type="received"><day>20</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Öztürk et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Öztürk et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64175-v1.pdf"/><abstract><sec><title>Background:</title><p>Adeno-associated virus (AAV)-mediated gene therapies are rapidly advancing to the clinic, and AAV engineering has resulted in vectors with increased ability to deliver therapeutic genes. Although the choice of vector is critical, quantitative comparison of AAVs, especially in large animals, remains challenging. </p></sec><sec><title>Methods:</title><p>Here, we developed an efficient single-cell AAV engineering pipeline (scAAVengr) to simultaneously quantify and rank efficiency of competing AAV vectors across all cell types in the same animal. </p></sec><sec><title>Results:</title><p>To demonstrate proof-of-concept for the scAAVengr workflow, we quantified - with cell-type resolution - the abilities of naturally occurring and newly engineered AAVs to mediate gene expression in primate retina following intravitreal injection. A top performing variant identified using this pipeline, K912, was used to deliver SaCas9 and edit the rhodopsin gene in macaque retina, resulting in editing efficiency similar to infection rates detected by the scAAVengr workflow. scAAVengr was then used to identify top-performing AAV variants in mouse brain, heart and liver following systemic injection. </p></sec><sec><title>Conclusions:</title><p>These results validate scAAVengr as a powerful method for development of AAV vectors. </p></sec><sec><title>Funding:</title><p>This work was supported by funding from the Ford Foundation, NEI/NIH, Research to Prevent Blindness, Foundation Fighting Blindness, UPMC Immune Transplant and Therapy Center, and the Van Sloun fund for canine genetic research.</p></sec></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Rhesus macaque</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000010</institution-id><institution>Ford Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Byrne</surname><given-names>Leah C</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>UPMC Immune Transplant and Therapy Center</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Byrne</surname><given-names>Leah C</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Van Sloun Fund for Canine Genetic Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Aguirre</surname><given-names>Gustavo D</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>F32EY023891</award-id><principal-award-recipient><name><surname>Byrne</surname><given-names>Leah C</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R24EY-022012</award-id><principal-award-recipient><name><surname>Schaffer</surname><given-names>David V</given-names></name><name><surname>Flannery</surname><given-names>John G</given-names></name><name><surname>Beltran</surname><given-names>William A</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01EY017549</award-id><principal-award-recipient><name><surname>Aguirre</surname><given-names>Gustavo D</given-names></name><name><surname>Beltran</surname><given-names>William A</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>P30EY001583</award-id><principal-award-recipient><name><surname>Aguirre</surname><given-names>Gustavo D</given-names></name><name><surname>Beltran</surname><given-names>William A</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>UG3MH120094</award-id><principal-award-recipient><name><surname>Pfenning</surname><given-names>Andreas R</given-names></name><name><surname>Beltran</surname><given-names>William A</given-names></name><name><surname>Byrne</surname><given-names>Leah C</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>DP2MH113095</award-id><principal-award-recipient><name><surname>Stauffer</surname><given-names>William R</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001818</institution-id><institution>Research to Prevent Blindness</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Byrne</surname><given-names>Leah C</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution>Foundation Fighting Blindness</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Byrne</surname><given-names>Leah C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Meike Visel, MV is an inventor on AAV capsid variants (US patent IDs: 10,214,785, 10,745,453). MV has also received royalty payments from UC Berkeley. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>José-Alain Sahel, JAS has served as a consultant (with no consulting fee)  for Pixium Vision, GenSight Biologics and SparingVision. Personal financial interests:  Pixium Vision, GenSight Biologics, Prophesee and Chronolife, SparingVision, SHARPEYE, Vegavect, Newsight Therapeutics. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf4"><p>David V Schaffer, DS is named as an inventor on patent applications on AAV capsid variants (U.S. Patent Applications No. 16/315,032, 16/486,681). DS is also a co-founder of 4D Molecular Therapeutics, and DS performs consultancy and owns stock options in this company. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf5"><p>Andreas R Pfenning, AP has received an honorarium from the University of Rhode Island, and has applied for patents on specific Nuclear-Anchored Independent Labeling System (PCT/US2020/038520 and PCT/US2020/038528). The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf6"><p>John G Flannery, JGF is an inventor on patent application on AAV capsid variants (U.S. Patent Application No. 16/315,032, 16/486,681). The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf7"><p>William A Beltran, WAB is an inventor on patent application on AAV capsid variants(16/315,032). The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf8"><p>William R Stauffer, WRS in an inventor on a patent application for methods of AAV capsid development (PCT/US2019/068489). The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf9"><p>Leah C Byrne, LB is named as an inventor on patent applications on AAV capsid variants and AAV screening methods (U.S. Patent Applications No. 16/315,032, 16/486,681, PCT/US2019/068489). LB has consulted on AAV-mediated gene therapy for Vedere Therapeutics, and is a named founder of Vegavect and Newsight Therapeutics. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All procedures were performed in compliance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research, and for canine studies with approval by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC # 803813), and for the NHP and mouse studies with approval from the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC #18042326).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Data, including count matrix files, raw fastq files as well as AAV/cell barcode tables generated from read quantification, have been uploaded to GEO under accession code GSE161645.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Byrne LC et al</collab></person-group><year iso-8601-date="2018">2018</year><source>Directed Evolution of AAV for Efficient Gene Delivery to Canine and Primate Retina - Raw counts of variants from deep sequencing</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6078/D1895R">https://doi.org/10.6078/D1895R</ext-link><comment>Dryad Digital Repository, D1895R</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Byrne LC et al</collab></person-group><year iso-8601-date="2021">2021</year><source>Directed Evolution of AAV for Efficient Gene Delivery to Canine and Primate Retina - Raw counts of variants from deep sequencing</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE161645">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE161645</ext-link><comment>NCBI Gene Expression Omnibus, GSE161645</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-64175-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>